US FDA has concerns about Granules - Ajinomoto OmniChem's Vizag API plant
US FDA inspectors have raised questions about an API manufacturing facility in India that is operated by Granules India and Ajinomoto OmniChem.
US FDA inspectors have raised questions about an API manufacturing facility in India that is operated by Granules India and Ajinomoto OmniChem.
DuPont has joined a Gates Foundation backed effort to develop low cost production methods for therapeutic proteins.
Center Point Clinical Services has launched what it is calling the “world's first site-less, technology CRO.”
Spanish regulators have found problems at a facility operated by immunotherapy producer Laboratorio Angulema.
XenoGesis has upgraded its spectroscopy capabilities in a deal with Thermo Fisher Scientific Inc.